Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP003709priorityCriticalpatent/ECSP003709A/en
Publication of ECSP003709ApublicationCriticalpatent/ECSP003709A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Una unidad de dosificación oral novedosa que comprende como un ingrediente activo el antidepresivo mirtazapina, donde la unidad de dosificación es del tipo que se desintegra oralmente. La unidad de dosificación, a pesar de desintegrarse rápidamente después de su administarciín oral , es bioequivalente con las tabletas convencionales, pero puede llevar a ventajas en términos de efectos secundarios, eficacia, efectos ansiolíticos, efectos mejoradores del sueño y comienza de la acción. Titulo unidad de dosificación oral que se desintegra oralmente conteniendo como ingrediente activo el antidepresivo mirtazapina.A novel oral dosage unit comprising the antidepressant mirtazapine as an active ingredient, where the dosage unit is of the orally disintegrating type. The dosage unit, despite rapidly disintegrating after oral administration, is bioequivalent with conventional tablets, but may lead to advantages in terms of side effects, efficacy, anxiolytic effects, sleep enhancing effects and onset of action. Title oral dosage unit that breaks down orally, containing the antidepressant mirtazapine as an active ingredient.
ECSP0037092000-10-112000-10-11
ORAL DOSING UNIT THAT ORALALLY DISintegrates CONTAINING THE ANTIDEPRESSANT MIRTAZAPINE AS AN ACTIVE INGREDIENT
ECSP003709A
(en)
A CAPILLARY LOTION WITH IMPROVED PROPERTIES IN ITS HAIR PROTECTIVE AND PREVENTIVE ACTION OF HIS FALL, AND REDUCTION OF THE EXTERNAL EFFECTS OF ANDROGENETIC ALOPECIA AND WITH THAT OF THE HAIR FALL.
Oral dosage form comprising at least one nicotine active agent, at least one bioadhesive material capable of forming a hydrogen bond with the nicotine active agent, and at least one rapidly releasing sensory impact agent; and its use to provide rapid relief from nicotine cravings (div. sol. 1825-04).
ORAL DOSING UNIT INCLUDING AN ANTAGONIST AGENT FOR PUMPS OF PROTONS AND EXCIPIENTS OF BASIC CHARACTER; PROCEDURE FOR PREPARATION, USEFUL TO TREAT DISEASES CAUSED BY AN INCREASED SECRETION OF GASTRIC ACIDS.
ORAL GALENIC FORMULATION INCLUDING KETOROLACO AND VITAMINS OF COMPLEX B, IN WHICH VITAMIN B6 IS IN AN EXTERNAL LAYER SEPARATED FROM THE REST OF ACTIVE PRINCIPLES